FORCED CHANGE IN RHEUMATOID ARTHRITIS TREATMENT DUE TO COVID-19 PANDEMIC: EFFECTS OF THE SWITCH FROM INTRAVENOUS TOCILIZUMAB TO SUBCUTANEOUS FORM
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Aim: Rheumatoid arthritis (RA) is one of the most common chronic systemic autoimmune diseases that primarily affecting the synovial joints, causing progressive joint disability and involving extra-articular symptoms. The American College of Rheumatology (ACR) criteria published in 2010 were used for the diagnosis and classification of RA. The aim of RA treatment was to achieve remission or low disease activity. For this purpose, steroids, non-steroidal anti-inflammatory drugs, and conventional synthetic and biological disease-modifying antirheumatic drugs are used. Material and Methods: Fifty-six patients with RA whose drug was switched from the intravenous (IV) tocilizumab form to the subcutaneous form in the Department of Internal Medicine Rheumatology-Immunology at Çukurova University Faculty of Medicine Research Hospital were included in the study. Patients with RA were diagnosed according to the criteria published by the 2010 ACR. The data were analyzed retrospectively. Results: Forty-seven patients had initially received IV tocilizumab treatment. The baseline mean disease activity score (DAS-28) values were 7.65, and the mean treatment duration was 24.6 months. The mean DAS-28 values in the 3rd month of the patients who received IV tocilizumab treatment at baseline were 3.6. The decrease in DAS-28 from baseline was statistically significant (p<0.0001). Conclusion: Consequently, subcutaneous tocilizumab therapy was effective and safe as IV therapy. The number of hospital admissions was less in the subcutan group, and Coronavirus disease-2019 (COVID-19) infection was less common. Subcutaneous therapy is a good alternative, especially during the pandemic period when patients can not easily access IV therapy and need to be isolated from the hospital.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- FORCED CHANGE IN RHEUMATOID ARTHRITIS TREATMENT DUE TO COVID-19 PANDEMIC: EFFECTS OF THE SWITCH FROM INTRAVENOUS TOCILIZUMAB TO SUBCUTANEOUS FORM
- Date Crossref
- 30/03/2023
- Éditeur
- Caleo
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Cukurova University pays non établi dans la noticeUniversité ou école supérieure
Cukurova University.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.